Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Current Liabilities: 2015-2024

Historic Total Current Liabilities for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $110.9 million.

  • Intellia Therapeutics' Total Current Liabilities fell 11.31% to $93.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.7 million, marking a year-over-year decrease of 11.31%. This contributed to the annual value of $110.9 million for FY2024, which is 3.78% down from last year.
  • Intellia Therapeutics' Total Current Liabilities amounted to $110.9 million in FY2024, which was down 3.78% from $115.2 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Total Current Liabilities registered a high of $126.6 million during FY2022, and its lowest value of $64.3 million during FY2020.
  • Over the past 3 years, Intellia Therapeutics' median Total Current Liabilities value was $115.2 million (recorded in 2023), while the average stood at $117.5 million.
  • Per our database at Business Quant, Intellia Therapeutics' Total Current Liabilities soared by 95.84% in 2021 and then dropped by 8.97% in 2023.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Total Current Liabilities stood at $64.3 million in 2020, then spiked by 95.84% to $125.8 million in 2021, then increased by 0.57% to $126.6 million in 2022, then fell by 8.97% to $115.2 million in 2023, then fell by 3.78% to $110.9 million in 2024.